SS-31 (Elamipretide): The Mitochondrial Peptide That Targets Cardiolipin

Most mitochondrial supplements have a delivery problem. Coenzyme Q10, NAD precursors like nicotinamide riboside, and oral glutathione all face the same issue: only a small fraction of what you swallow ever reaches the inner mitochondrial membrane, which is where mitochondrial dysfunction actually originates.

SS-31, also known by its clinical name elamipretide, was engineered specifically to solve this problem. It is a small synthetic tetrapeptide — just four amino acids (D-Arg-Dmt-Lys-Phe-NH2) — designed to accumulate at extremely high concentrations within the inner mitochondrial membrane. Published research from the Szeto group at Weill Cornell has measured a 5,000-fold concentration gradient, meaning the drug reaches the site of action at thousands of times the plasma concentration.

This is not a bioavailability claim extrapolated from one mouse study. SS-31 has been through Phase II and Phase III human trials under the names elamipretide and Bendavia for conditions as varied as Barth syndrome, heart failure, primary mitochondrial myopathy, and age-related macular degeneration. The FDA granted it Fast Track designation for Barth syndrome in 2017.

Inside every mitochondrion are stacks of folded membrane (cristae) densely packed with electron transport chain (ETC) complexes. The inner mitochondrial membrane contains a phospholipid found almost nowhere else in the body: cardiolipin. Cardiolipin is essential for the structural integrity of the ETC and for the proper function of cytochrome c, a key electron carrier.

With age, disease, and ischemia, cardiolipin decreases in quantity and changes in composition (specifically, it loses its linoleic acid content). When cardiolipin is damaged, cytochrome c dissociates from the inner membrane and starts acting as a peroxidase — generating reactive oxygen species (ROS) rather than shuttling electrons. The result is lower ATP output, higher oxidative stress, and the gradual bioenergetic decline that underlies many diseases of aging.

SS-31 binds selectively to cardiolipin in the inner mitochondrial membrane. This binding stabilises the cardiolipin–cytochrome c interaction, keeping cytochrome c functioning as an electron carrier rather than a ROS generator. It is not a conventional antioxidant. It does not scavenge free radicals. It restores the upstream machinery that stops producing them in the first place.

This mechanism is genuinely novel in mitochondrial pharmacology. Most antioxidants try to mop up damage downstream. SS-31 addresses the root cause by protecting cardiolipin function directly.

SS-31 has the unusual distinction among research peptides of being tested in multiple rigorous Phase II and Phase III trials in humans.

The TAZPOWER trial (2018) studied elamipretide in Barth syndrome, a rare genetic condition causing cardiolipin deficiency. Patients showed measurable improvements in the 6-minute walk test and cardiac function during the open-label extension phase. This remains the strongest clinical signal for the cardiolipin mechanism in a genetically defined population.

The MMPOWER trials in primary mitochondrial myopathy tested daily subcutaneous elamipretide at 40 mg for 24 weeks. The primary endpoint (6-minute walk distance) was not met, but pre-specified subgroup analyses showed benefit in patients with more severe baseline impairment. The programme continues in follow-on trials with refined patient selection.

The EMBRACE STEMI trial tested elamipretide at the time of coronary reperfusion after heart attack. Cardiac imaging showed reduced infarct size in the treatment group, consistent with mitochondrial protection during ischemia-reperfusion injury.

The ReCLAIM-2 trial in dry age-related macular degeneration showed reduction in drusen volume and improvements in low-luminance visual function with daily subcutaneous elamipretide at 40 mg.

Taken together, the trial programme shows a consistent signal of mitochondrial protection across multiple organ systems. The primary endpoints have not always been met, which is typical for drugs targeting chronic age-related diseases, but the mechanistic coherence is strong.

The clinical trial dose used in almost every elamipretide study has been 40 mg once daily by subcutaneous injection over 12 to 24 weeks. This is the dose backed by pharmacokinetic modelling, and it is significantly higher than what most community protocols describe for research use.

Community protocols circulating in biohacking forums typically describe 5 mg to 10 mg once daily, sometimes with cycling (several weeks on, several weeks off). There is no published clinical evidence that these lower doses produce the same mitochondrial effects seen at 40 mg. They may still produce some benefit given the 5,000-fold concentration gradient, but the evidence for this is anecdotal rather than clinical.

The half-life of elamipretide in plasma is approximately 2 to 3 hours, but because it accumulates in mitochondria the functional duration is much longer. Most protocols call for once-daily dosing for this reason.

Anyone considering SS-31 for research purposes should be aware that the clinical dose is at the high end of what any community protocol describes, and that individual tolerability at clinical doses is generally good per the published trial data.

In clinical trials, SS-31 has shown a favourable safety profile. The most common adverse events reported across multiple trials were injection site reactions (pain, redness, induration) in 20 to 40 percent of patients — expected for any daily subcutaneous peptide. Headache and mild gastrointestinal symptoms were reported less frequently.

No drug-related serious adverse events were attributed to elamipretide in the published trial programme. The safety database now includes thousands of patient-exposure-days at the 40 mg daily dose over 24 weeks.

Longer-term safety data (multi-year) does not yet exist in the public record. Interactions with common medications have not been extensively studied. Users of research peptides should also note that formulations available outside clinical trials have not been subject to the same manufacturing oversight as the investigational product used in the trials.

For readers trying to understand where SS-31 fits in a longevity stack, it is useful to contrast it with other mitochondrial interventions.

NAD precursors (NMN, NR, nicotinamide riboside) increase NAD+ availability, which supports sirtuin activity and ATP production. They act at a different level of mitochondrial biology (substrate availability) and do not protect cardiolipin directly.

Coenzyme Q10 and ubiquinol support the electron transport chain as an electron shuttle. They can help in conditions of CoQ10 deficiency but have poor mitochondrial penetration at oral doses, which SS-31 was specifically engineered to overcome.

MitoQ is a targeted form of ubiquinol designed to concentrate in mitochondria. It does accumulate in mitochondria, but its mechanism is to act as an antioxidant rather than to stabilise cardiolipin. It has a smaller published clinical trial programme than elamipretide.

Exercise, particularly zone-2 cardio, increases mitochondrial biogenesis and remains the single most-validated intervention for improving mitochondrial function. SS-31 is not a substitute for this; it addresses a different problem (protecting existing mitochondria rather than making new ones).

MOTS-c, a peptide encoded by the mitochondrial genome itself, is often discussed alongside SS-31 but acts through completely different pathways (AMPK activation, insulin sensitisation, exercise mimetic).

Elamipretide is not registered on the Australian Register of Therapeutic Goods (ARTG) and is not available as a prescription therapeutic in Australia as of April 2026.

SS-31 as a research peptide is available through research-chemical vendors for laboratory research use only. It is classified as a Schedule 4 substance when intended for therapeutic use in humans. Importing peptides for personal use is governed by the TGA's Personal Importation Scheme, which requires a prescription from an Australian doctor for any therapeutic product.

For clinicians interested in accessing elamipretide for a patient with a qualifying condition (Barth syndrome, mitochondrial myopathy), the Special Access Scheme (SAS) pathway may provide a route. This requires documented clinical need and TGA approval and is distinct from the research-peptide supply chain.

For the full SS-31 peptide profile including detailed mechanism diagrams and dosing tables, see /peptides/ss-31.

For a comparison with the other major mitochondrial peptide in active research, see our MOTS-c guide at /guides/mots-c-exercise-mimetic-peptide.

For readers new to peptides generally, start with the reconstitution guide at /guides/reconstitution-guide-beginners and the storage guide at /guides/how-to-store-peptides.

For vendor information, our rated vendors page at /vendors covers suppliers in Australia, the US, UK, and Canada with third-party COA information and community ratings.

This guide is for educational and informational purposes only and does not constitute medical advice. SS-31 (elamipretide) is an investigational drug not approved for human use outside of clinical trials in Australia, the United States, or most other jurisdictions. Any use should be discussed with a qualified healthcare professional. The research information reflects the published scientific literature as of April 2026. Research peptides sourced outside the clinical trial supply chain are not subject to the same manufacturing standards as the investigational product.